Compugen reported $-9.02M in Operating Profit for its fiscal quarter ending in March of 2026.





Operating Profit Change Date
Arca Biopharma USD -34.43M 326K Dec/2025
aTyr Pharma USD -128K 24.6M Mar/2026
Bio Path USD -488K 4.07M Sep/2025
Brainstorm Cell Therapeutics USD -2.24M 197K Dec/2025
Cara Therapeutics USD -5.94M 3.55M Sep/2025
Clal Biotechnology ILS -1.74M 7.46M Dec/2022
Compugen USD -9.02M 65.06M Mar/2026
Immunic USD -23.33M 2.67M Dec/2025
Minerva Neurosciences USD -21.85M 17.48M Dec/2024
RedHill Biopharma USD -4.22M 1.8M Jun/2024
TherapeuticsMD USD -1.18M 40K Jun/2024